Quanterix CEO Leads Webinar on How Digital Biomarkers are Empowering Drug Development
Top researchers join the discussion on biomarker innovations for accelerating drug development
Brief
The webinar, Disrupting
Drug Development with Digital Biomarkers and the Power of
“Ultra sensitive digital biomarkers are catalyzing the potential for diseases to be detected less invasively and earlier in the disease cascade when theoretically the disease is more treatable,” said Hrusovsky. “When deployed in drug development, digital biomarkers have the potential to complement traditional clinical endpoints, providing researchers with enhanced mechanistic understanding and measurement of a drug's efficacy and toxicity at an individual patient level. These advances in digital biomarker measurement offer the potential for ushering in new treatment options and improving human health.”
Hrusovsky will be joined by world-renowned researchers who will share how they have deployed biomarker technology in the areas of neurology and oncology research, including:
-
Dr.
Henrik Zetterberg , Professor of Neurochemistry and Head of theDepartment of Psychiatry and Neurochemistry ,Sahlgrenska Academy at theUniversity of Gothenburg -
Dr.
Andrew Nixon , Associate Professor in Medicine, Member of theDuke Cancer Institute
Designed for a wide range of stakeholders in healthcare, the webinar
will provide a vision for the potential of digital biomarkers and
This webinar is open to the public and can be accessed by registering here, or through the Webinars page within the Resources & News section of the Quanterix website at www.quanterix.com.
About
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Words
such as "may," "will," "expect," "plan," "anticipate," "estimate,"
"intend" and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are intended to
identify forward-looking statements. Forward-looking statements in this
news release are based on Quanterix’s expectations and assumptions as of
the date of this press release. Each of these forward-looking statements
involves risks and uncertainties. Factors that may cause Quanterix’
actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed
in Quanterix’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20180918005701/en/
Source:
PAN Communications
Lindsay Poole, 617-502-4300
quanterix@pancomm.com